Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Adaptive Biotechnologies

Evaluate

Thumbnail
December 02, 2021

The T-cell test bronze goes to Qiagen

Thumbnail
March 08, 2021

Adaptive’s Covid-19 T-cell test hits the US

As with antibodies, the next step will be proving that T-cells can grant immunity.

Article image
Vantage logo
November 12, 2020

Qiagen enters the T-cell testing fray

At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.

Article image
Vantage logo
April 07, 2020

Covid-19 oils the wheels of business development

Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.

Article image
Vantage logo
January 21, 2020

Poor fourth quarter mars strong year for medtech floats

The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.

Article image
Vantage logo
July 25, 2019

Livongo enters the medtech float hall of fame

The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.

Article image
Vantage logo
July 12, 2019

Few medtechs go public, but those that do, do nicely

Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.

Vantage logo
July 03, 2019

Share price catalysts: June 2019

Vantage logo
March 16, 2017

Corporate venture capital – saviour of medtech?

Vantage logo
January 19, 2016

Huge medtech venture rounds mean start-ups starve

Vantage logo
November 04, 2015

Marked drop in early funding could endanger medtech’s future

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up